Endothelin receptor blockade potentiates FasL-induced apoptosis in colon carcinoma cells via the protein kinase C-pathway
- PMID: 11078419
- DOI: 10.1097/00005344-200036051-00103
Endothelin receptor blockade potentiates FasL-induced apoptosis in colon carcinoma cells via the protein kinase C-pathway
Abstract
An imbalance between proliferation and apoptosis is important in tumor progression. Endothelin-1 (ET-1) has vasoconstricting and mitogenic activities and may be involved in apoptosis regulation. We found that ET-1 and FasL systems were colocalized in human colon tumors and that ET-1 was secreted by human (HT-29, SW480) and rat (PROb, REGb) colon carcinoma cell lines. Bosentan, a mixed endothelin-A- and -B- (ET(A)/ET(B)) receptor antagonist, potentiated FasL- (APO-1, CD95) induced apoptosis in these cells. The specific inhibition of enzymes involved in ceramide production did not restore survival of cells exposed to FasL and bosentan. Inhibition of PKC with bisindolylmaleimide IX enhanced FasL-induced apoptosis in HT-29, PROb and REGb cells in the absence of bosentan. These results suggest that ET-1 is an autocrine survival factor able to protect colon carcinoma cells against FasL-induced apoptosis, involving the protein kinase C (PKC) but not the sphingomyelin-ceramide signaling transduction pathways.
Similar articles
-
Endothelin-receptor antagonists are proapoptotic and antiproliferative in human colon cancer cells.Br J Cancer. 2003 Mar 10;88(5):788-95. doi: 10.1038/sj.bjc.6600810. Br J Cancer. 2003. PMID: 12618891 Free PMC article.
-
Endothelin receptor blockade potentiates FasL-induced apoptosis in rat colon carcinoma cells.Int J Cancer. 2000 Apr 15;86(2):182-7. doi: 10.1002/(sici)1097-0215(20000415)86:2<182::aid-ijc6>3.0.co;2-g. Int J Cancer. 2000. PMID: 10738244
-
Targeting the endothelin axis in human melanoma: combination of endothelin receptor antagonism and alkylating agents.Exp Biol Med (Maywood). 2006 Jun;231(6):1111-9. Exp Biol Med (Maywood). 2006. PMID: 16741059
-
Altered mechanisms of apoptosis in colon cancer: Fas resistance and counterattack in the tumor-immune conflict.Ann N Y Acad Sci. 2000 Jun;910:178-92; discussion 193-5. doi: 10.1111/j.1749-6632.2000.tb06708.x. Ann N Y Acad Sci. 2000. PMID: 10911913 Review.
-
On the role and significance of Fas (Apo-1/CD95) ligand (FasL) expression in immune privileged tissues and cancer cells using multiple myeloma as a model.Leuk Lymphoma. 1998 Nov;31(5-6):477-90. doi: 10.3109/10428199809057607. Leuk Lymphoma. 1998. PMID: 9922038 Review.
Cited by
-
Endothelin and the tumor microenvironment: a finger in every pie.Clin Sci (Lond). 2024 Jun 5;138(11):617-634. doi: 10.1042/CS20240426. Clin Sci (Lond). 2024. PMID: 38785410 Free PMC article. Review.
-
Endothelin-receptor antagonists are proapoptotic and antiproliferative in human colon cancer cells.Br J Cancer. 2003 Mar 10;88(5):788-95. doi: 10.1038/sj.bjc.6600810. Br J Cancer. 2003. PMID: 12618891 Free PMC article.
-
Endothelin-1 as a Mediator of Heme Oxygenase-1-Induced Stemness in Colorectal Cancer: Influence of p53.J Pers Med. 2021 Jun 4;11(6):509. doi: 10.3390/jpm11060509. J Pers Med. 2021. PMID: 34199777 Free PMC article.
-
Antivascular therapy for multidrug-resistant ovarian tumors by macitentan, a dual endothelin receptor antagonist.Transl Oncol. 2012 Feb;5(1):39-47. doi: 10.1593/tlo.11286. Epub 2012 Feb 1. Transl Oncol. 2012. PMID: 22348175 Free PMC article.
-
Endothelin receptor antagonists: rationale, clinical development, and role in prostate cancer therapeutics.Curr Oncol Rep. 2006 Mar;8(2):108-13. doi: 10.1007/s11912-006-0045-1. Curr Oncol Rep. 2006. PMID: 16507220
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials